Original Research
Published on 27 Apr 2017
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
in Antimicrobials, Resistance and Chemotherapy
- 5,411 views
- 33 citations








